The persistence of SARS-CoV-2 neutralizing antibodies after COVID-19: A one-year observation. Is a SARS-CoV-2 vaccination booster dose necessary?

被引：1

作者：

Tworek, Adam ^{[1
]}

Jaron, Krzysztof ^{[1
]}

Cicha, Malgorzata ^{[2
]}

Rydzewski, Andrzej ^{[3
,4
]}

Wierzba, Waldemar ^{[5
,6
]}

Zaczynski, Arturza ^{[5
]}

Krol, Zbigniew ^{[5
]}

Rydzewska, Grazyna ^{[1
,7
]}

机构：

[1] Minist Interior & Adm, Cent Clin Hosp, Clin Dept Internal Med & Gastroenterol, Inflammatory Bowel Dis Unit, Warsaw, Poland

[2] Minist Interior & Adm, Diagnost Lab Cent Clin Hosp, Warsaw, Poland

[3] Minist Interior & Adm, Cent Clin Hosp, Dept Internal Med Nephrol & Transplantat Med, Warsaw, Poland

[4] Ctr Postgrad Med Educ, Dept Internal Med Nephrol & Transplantat Med, Warsaw, Poland

[5] Minist Interior & Adm, Cent Clin Hosp, Warsaw, Poland

[6] Univ Humanities & Econ Lodz, Satellite Campus Warsaw, Warsaw, Poland

[7] Jan Kochanowski Univ, Coll Med, Kielce, Poland

来源：

CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY | 2023年 / 48卷 / 02期

关键词：

COVID-19; SARS-CoV-2; vaccination; SARS;

D O I：

10.5114/ceji.2023.126206

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Introduction: The aim of this study was to investigate the persistence of SARS-CoV-2 neutralizing antibodies (NAbs) one year after contracting COVID-19.Material and methods: The study included 38 patients - 34 men and 4 women - suffering from COVID-19 between March 15 and May 26, 2020. The median age in the group was 31 years, ranging from 22 to 67 years. The levels of neutralizing antibodies were measured at three timepoints - baseline, 6 months, and 12 months. The primary endpoint was a post-infection positive result for NAbs (> 15 AU/ml; Results: The median level of NAbs after 12 months was 26.5 AU/ml. At the end of observation (12 months), 21 of the 38 patients had a NAb level of >15 AU/ml (positive). The median antibody halflife was 5.8 months.Conclusions: A high percentage of the patients maintained positive levels of antibodies 6 and 12 months after COVID-19 infection. The dynamics of the antibody level decline suggests the need for booster vaccination at least once a year.

引用

页码：92 / 96

页数：5

共 31 条

[1] Aguila-Gordo Daniel, 2021, Rev Esp Geriatr Gerontol, V56, P259, DOI 10.1016/j.regg.2020.09.006
[2] EFFECTS OF A NEW HUMAN RESPIRATORY VIRUS IN VOLUNTEERS
BRADBURNE, AF
BYNOE, ML
TYRRELL, DAJ
[J]. BMJ-BRITISH MEDICAL JOURNAL, 1967, 3 (5568): : 767 - +
[3] Disappearance of antibodies to SARS-associated coronavirus after recovery
Cao, Wu-Chun
Liu, Wei
Zhang, Pan-He
Zhang, Fang
Richardus, Jan H.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (11) : 1162 - 1163
[4] Duration of immune protection of SARS-CoV-2 natural infection against reinfection
Chemaitelly, Hiam
Nagelkerke, Nico
Ayoub, Houssein H.
Coyle, Peter
Tang, Patrick
Yassine, Hadi M.
Al-Khatib, Hebah A.
Smatti, Maria K.
Hasan, Mohammad R.
Al-Kanaani, Zaina
Al-Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar Hassan
Latif, Ali Nizar
Shaik, Riyazuddin Mohammad
Abdul-Rahim, Hanan F.
Nasrallah, Gheyath K.
Al-Kuwari, Mohamed Ghaith
Butt, Adeel A.
Al-Romaihi, Hamad Eid
Al-Thani, Mohamed H.
Al-Khal, Abdullatif
Bertollini, Roberto
Abu-Raddad, Laith J.
[J]. JOURNAL OF TRAVEL MEDICINE, 2022, 29 (08)
[5] SARS-CoV-2 Mutations and their Viral Variants
Cosar, Begum
Karagulleoglu, Zeynep Yagmur
Unal, Sinan
Ince, Ahmet Turan
Uncuoglu, Dilruba Beyza
Tuncer, Gizem
Kilinc, Bugrahan Regaip
Ozkan, Yunus Emre
Ozkoc, Hikmet Ceyda
Demir, Ibrahim Naki
Eker, Ali
Karagoz, Feyzanur
Simsek, Said Yasin
Yasar, Bunyamin
Pala, Mehmetcan
Demir, Aysegul
Atak, Irem Naz
Mendi, Aysegul Hanife
Bengi, Vehdi Umut
Sevel, Guldane Cengiz
Altuntas, Evrim Gunes
Kilic, Pelin
Demir-Dora, Devrim
[J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2022, 63 : 10 - 22
[6] Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
Deng, Wei
Bao, Linlin
Liu, Jiangning
Xiao, Chong
Liu, Jiayi
Xue, Jing
Lv, Qi
Qi, Feifei
Gao, Hong
Yu, Pin
Xu, Yanfeng
Qu, Yajin
Li, Fengdi
Xiang, Zhiguang
Yu, Haisheng
Gong, Shuran
Liu, Mingya
Wang, Guanpeng
Wang, Shunyi
Song, Zhiqi
Liu, Ying
Zhao, Wenjie
Han, Yunlin
Zhao, Linna
Liu, Xing
Wei, Qiang
Qin, Chuan
[J]. SCIENCE, 2020, 369 (6505) : 818 - +
[7] Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Kinetics and Protection Duration
Dimeglio, Chloe
Herin, Fabrice
Da-Silva, Isabelle
Porcheron, Marion
Martin-Blondel, Guillaume
Chapuy-Regaud, Sabine
Izopet, Jacques
[J]. CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E924 - E925
[8] Persistence of IgG response to SARS-CoV-2
Duysburgh, Els
Mortgat, Laure
Barbezange, Cyril
Dierick, Katelijne
Fischer, Natalie
Heyndrickx, Leo
Hutse, Veronik
Thomas, Isabelle
Gucht, Steven Van
Vuylsteke, Bea
Arien, Kevin K.
Desombere, Isabelle
[J]. LANCET INFECTIOUS DISEASES, 2021, 21 (02) : 163 - 164
[9] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti, Pedro M.
Ewer, Katie J.
Aley, Parvinder K.
Angus, Brian
Becker, Stephan
Belij-Rammerstorfer, Sandra
Bellamy, Duncan
Bibi, Sagida
Bittaye, Mustapha
Clutterbuck, Elizabeth A.
Dold, Christina
Faust, Saul N.
Finn, Adam
Flaxman, Amy L.
Hallis, Bassam
Heath, Paul
Jenkin, Daniel
Lazarus, Rajeka
Makinson, Rebecca
Minassian, Angela M.
Pollock, Katrina M.
Ramasamy, Maheshi
Robinson, Hannah
Snape, Matthew
Tarrant, Richard
Voysey, Merryn
Green, Catherine
Douglas, Alexander D.
Hill, Adrian V. S.
Lambe, Teresa
Gilbert, Sarah C.
Pollard, Andrew J.
[J]. LANCET, 2020, 396 (10249) : 467 - 478
[10] Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Grifoni, Alba
Weiskopf, Daniela
Ramirez, Sydney, I
Mateus, Jose
Dan, Jennifer M.
Moderbacher, Carolyn Rydyznski
Rawlings, Stephen A.
Sutherland, Aaron
Premkumar, Lakshmanane
Jadi, Ramesh S.
Marrama, Daniel
de Silva, Aravinda M.
Frazier, April
Carlin, Aaron F.
Greenbaum, Jason A.
Peters, Bjoern
Krammer, Florian
Smith, Davey M.
Crotty, Shane
Sette, Alessandro
[J]. CELL, 2020, 181 (07) : 1489 - +

← 1 2 3 4 →